SELLAS Life Sciences (SLS) Total Non-Current Liabilities (2010 - 2022)
SELLAS Life Sciences (SLS) posted quarterly Total Non-Current Liabilities of $16.1 million for Q4 2022, up 185.72% year-over-year from $5.6 million in Q4 2021, and up 21.6% quarter-over-quarter from $13.2 million in Q3 2022.
SELLAS Life Sciences (SLS) Total Non-Current Liabilities (2010 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Total Non-Current Liabilities for 13 consecutive years, with $16.1 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Total Non-Current Liabilities rose 185.72% year-over-year to $16.1 million; the TTM figure through Dec 2022 stood at $16.1 million (up 185.72% YoY), while the FY2022 annual figure was $16.1 million, up 185.72% from the prior year.
- Total Non-Current Liabilities improved to $16.1 million in Q4 2022 per SLS's latest filing, from $13.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $30.1 million in Q1 2018 and bottomed at $3.9 million in Q1 2020.
- Historically, Total Non-Current Liabilities has averaged $10.9 million across 5 years, with a median of $7.2 million in 2019.
- Annual changes were most pronounced in 2019 — Total Non-Current Liabilities slumped 79.9% — and 2022, when it jumped 185.72%.
- SELLAS Life Sciences' Total Non-Current Liabilities stood at $7.3 million in 2018, then dropped by 23.69% to $5.6 million in 2019, then jumped by 140.1% to $13.5 million in 2020, then sank by 58.14% to $5.6 million in 2021, then jumped by 185.72% to $16.1 million in 2022.
- Business Quant data shows SLS's Total Non-Current Liabilities at $16.1 million in Q4 2022, $13.2 million in Q3 2022, and $13.0 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 16.09 Mn |
| Sep 30, 2022 | 13.23 Mn |
| Jun 30, 2022 | 12.97 Mn |
| Mar 31, 2022 | 17.11 Mn |
| Dec 31, 2021 | 5.63 Mn |
| Sep 30, 2021 | 6.31 Mn |
| Jun 30, 2021 | 5.31 Mn |
| Mar 31, 2021 | 7.07 Mn |
| Dec 31, 2020 | 13.46 Mn |
| Sep 30, 2020 | 5.38 Mn |
| Jun 30, 2020 | 5.54 Mn |
| Mar 31, 2020 | 3.91 Mn |
| Dec 31, 2019 | 5.60 Mn |
| Sep 30, 2019 | 6.01 Mn |
| Jun 30, 2019 | 5.89 Mn |
| Mar 31, 2019 | 7.26 Mn |
| Dec 31, 2018 | 7.34 Mn |
| Sep 30, 2018 | 14.69 Mn |
| Jun 30, 2018 | 29.30 Mn |
| Mar 31, 2018 | 30.10 Mn |